Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Poster Icons

Marie Brown Etris Oral Abstract Award

Highest Scoring Poster Abstract

Rapid-Fire Poster Talks

Late Breaking Abstract

People's Choice Award Nominee

People's Choice Award Winner

Wound Healing Society

Virtual Poster Hall Sponsor

Back

Rate ePoster109 Views

Case Series/Study

(CS-050) Use of Borate Based Bioactive Glass Matrix in the Treatment of Stage 4 Pressure Injury

Thursday, May 16, 2024

7:30 PM – 8:30 PM East Coast USA Time

Jai Joshi, BS – Visiting Scholar, Surgery, Northwell Health; Amit Rao, MD – Research Project Manager, Surgery, Northwell Health, Department of Surgery; Julie Isgro, MSN – Nurse Practitioner, Surgery, Northwell Health; Alisha Oropallo, MD – Clinical Director, Surgery, Northwell Health

Introduction: Pressure injuries (PI) impose a significant burden on patients. Our aim was to assess the efficacy of borate based bioactive glass matrix (BBBGM)1 in a case series of chronic non-healing stage 4 sacral PI.

Methods: Cases with sacral PI stage 4 at a tertiary wound center were consented for treatment. After cleansing and debridement, the BBBGM was applied with a wound veil and topical foam as a secondary dressing. Each subject had previously been treated with advanced wound healing products such as NPWT, topical oxygen, and cellular tissue products but healing had stalled. Each case’s standard of care (SOC) wound data was compared to post-BBBGM use data. Descriptive statistics were used cross section area (cm2) and volume (cm3) in each patient.

Results:

CASE 1: 66-year-old female with hypertension, congestive heart failure, and morbid obesity presented with a sacral ulcer. At baseline SOC Q3 2022, wound volume was 4.81cm3. Four doses of BBBGM were applied over 56 days. The final volume was 0.69 cm3. The subject reported no issues associated with product use. BBBGM area and volume change was significant compared to SOC by t-test p</span><0.05.

CASE 2: 70-year-old female with a history of hypertension, hyperlipidemia, DM type 2, and CKD stage 3 presented with a sacral ulcer. SOC in Q1 2023, the wound bed displayed granulated muscle base. BBBGM was applied three times over 55 days. The subject reported no issues associated with product use and stated that drainage decreased. The pre-BBBGM depth 1.8cm and area 0.6 cm2 achieved closure over 8 weeks.

CASE 3: 68-year-old female with a history of hypertension, hyperlipidemia, morbid obesity, and aortic stenosis presented with a sacral ulcer. SOC data was from Q4 2022 through Q2 2023 and pre-BBBGM wound depth measured 1.5 cm, and the area 0.96 cm2. The wound edges appeared macerated, with granulated muscle base. Six doses were applied over 139 days. The depth reduced to 1cm. Both SOC and BBBGM improved closure.

Discussion: This case series demonstrates the safety and efficacy of a borate based bioactive glass matrix to effectively improve closure in stage 4 sacral PI. 